Infections in pre-RA: a cause or a consequence? Rheumatoid arthritis is known to be associated with a higher risk of infections, and this occurs for multiple reasons: immune dysfunction, systemic inflammation, comorbidities, and treatments. https://t.co/N91Goop92l https://t.co/yvnRrsHSCB

• https://bit.ly/3AaHTiP

Dr. Michael Holers on preclinical RA "Individuals who are anti-CCP positive are not clinically well. We just can't see what is going on" @RheumNow #ACR22

Emphasis that drug holiday is NOT drug retirement in osteoporosis. Ideal time to re-initiate is quite uncertain however. Continue to monitor DEXA and fracture risk factors. @RheumNow #ACR22 #osteoporosis https://t.co/iLKrxdzpAR

Valero et al. Combined biologics in PsA. @RheumNow #ACR22 Abstr1044 https://t.co/7nNf0Ktf0M https://t.co/CIE9BnBFvx

• Combined Biological or Targeted Therapy in Spondyloarthritis: Experience from a…

The Great Debate! Should you treat pre-clinical RA? First - likelihood of RA? If you have +ACPA or RF in sputum, there is 67% chance of developing clinical RA! @RheumNow #ACR22 https://t.co/K7pUhvbEDR

💠CYC confers a 27% risk of congenital malformations and ⬆️miscarriage rate 💠Contraception is recommended during use and 3 mos after tx #ACR22 @Rheumnow https://t.co/A73vCMZdxd

Can we predict PsA incidence and prevalence trends? Germany long-term projection 2040 3 scenarios: 1. increase 5%/yr 2. stable 3. decrease 5%/yr. Best scenario (3) = peak diagnoses in 2028. Are medical resources ready for it? https://t.co/ws87zDukuM Abs#1019 #ACR22 @Rheumnow https://t.co/dqkfrag0w2

• Number of Patients with Psoriatric Arthritis (PsA) in Germany Until 2040: Proje…

Atypical femoral fracture risk increases over time. Risk decreases slowly as well with time off treatment. Absolute risk remains relatively low however. @RheumNow #ACR22 #osteoporosis https://t.co/pcIfhRW4WJ

💉COVID-19 vaccination in pregnant pts with rheumatic disease💉 🤰⬇️pre term births in vaccinated 🤰PPROM ⬆️ unvaccinated ✅More support 4 importance of covid vacc in our 🤰 Stellar work from covid GRA- Fantastic presentation by @Sineadm15 #ACR22 @RheumNow @RichardPAConway https://t.co/LLaLJSqS6W

Good BMD gains in switching BP->denosumab, especially in first few years. #sequentialtherapy @RheumNow #ACR22 #osteoporosis https://t.co/t1hItKn8sB

Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less than 5 Mg/kg/day leads to increased hospitalizations for #SLE flares abst#1654 #ACR22 #PressConference @rheumnow https://t.co/GGnnl14cy9

• Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizat…

Phase 1 data shows Ebdarokimab (IL12/23i) safe and well tolerated in moderate to severe plaque psoriasis patients. Abs 0752 #ACR22 @RheumNow https://t.co/QqTE4WJtDa https://t.co/eMaEurZAr0

• A Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics an…

The great debate Next steps to develop RA prevention Kevin Deane “It’s time to move from disease modifying drugs to disease modifying therapeutic approaches” #ACRdebate #ACR22 @RheumNow https://t.co/3vt58sXlDx

Advancing Telemedicine in Rheumatology 'We all became Zoomatologists (Zheum-atologists?) since COVID.' -Jack Cush @RheumNow @RheumNow #ACR22

Pts w/ pre-existing rheumatic conditions 3.6 times likelier to new rheumatic disease features or worsening disease after starting ICI for melanoma, Abs 0756 #ACR22 @RheumNow https://t.co/s1f1QxmJzA https://t.co/6cKllBzqJn

• Rheumatic Toxicities of Immune Checkpoint Inhibitors in Patients with Advanced …